

Neuroendocrine Tumor Treatment Market Forecasts to 2034 – Global Analysis By Service (Safety Pharmacology, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies, Toxicology Testing, Chemistry, Compound Management and Other Services), Animal Model (Large Animal Model and Small Animal Model), Model Type, End User and By Geography

<https://marketpublishers.com/r/N523FEC6322AEN.html>

Date: April 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: N523FEC6322AEN

Abstracts

According to Statistics MRC, the Global Neuroendocrine Tumor Treatment Market is accounted for \$4007.0 million in 2026 and is expected to reach \$12867.5 million by 2034 growing at a CAGR of 15.7% during the forecast period. Neuroendocrine tumor treatment encompasses a range of medical interventions aimed at managing neuroendocrine tumors (NETs), a diverse group of rare neoplasms that arise from neuroendocrine cells. These tumors can develop in a number of organs, although they most frequently affect the pancreas and digestive system.

According to the National Center for Advancing Translational Sciences – Genetic and Rare Diseases Information Center data updated in November 2021, there were around 3,000 to 30,000 people in the United States affected by carcinoid tumor, which usually develops in the gastrointestinal tract or the lungs.

Market Dynamics:

Driver:

Expansion of neuroendocrine tumor treatments

The growing number of patients has encouraged pharmaceutical and biotechnology businesses to spend money on research and development for better patient outcomes and appropriate interventions resulting from early diagnosis. Several factors including improved diagnostic techniques, greater awareness, and changes in lifestyle, precision medicine, guided by molecular profiling, allows for personalized therapeutic strategies, which are driving this market size.

Restraint:

High treatment costs

Patients may find it difficult to receive high-cost treatments, especially if they have limited financial resources or insufficient insurance, due to the expense of prescription drugs, medical procedures, hospital stays, and follow-up care. The high expense of treating neuroendocrine tumors may make it difficult for healthcare systems to devote enough funding, which could restrict the accessibility and affordability of these essential treatments. Furthermore, insurance coverage gaps and high out-of-pocket expenses further impede patient access to optimal treatment.

Opportunity:

Advancements in research developments

Molecular profiling has emerged as a key aspect of NET research, enabling the identification of specific biomarkers and genetic mutations associated with these tumors. These discoveries have led to the introduction of innovative treatment options such as somatostatin analogs, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). Moreover, the ongoing scientific discoveries contribute to a deeper understanding of molecular mechanisms and genetic factors, ultimately enhancing patient outcomes and expanding the range of available treatments, thereby driving market growth.

Threat:

Lack of awareness

Neuroendocrine tumors (NETs) are difficult to detect since they are comparatively

uncommon and present with a variety of symptoms. These tumors may not be well known to many medical professionals, which could cause delayed or incorrect diagnoses. Additionally, lack of knowledge on NETs, causes them to incorrectly interpret symptoms and delay seeking medical attention. This lack of awareness also extends to the broader medical community, potentially leading to suboptimal management of NET cases.

Covid-19 Impact

The market for neuroendocrine tumor treatments was adversely affected by the COVID-19 pandemic. Patient outcomes were impacted by delayed neuroendocrine tumor detection and treatment as a result of lockdowns and restricted capacity in healthcare facilities. Clinical trials for innovative medicines were restricted, and the availability of healthcare services was stretched due to the reallocation of resources and attention toward addressing the pandemic. Furthermore, concerns about immunosuppression and financial limitations on healthcare systems also affected the willingness to start or maintain therapy, gradually hindering the market size.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is estimated to hold the largest share. Chemotherapy is typically considered in cases where surgery and other treatments are less effective, often in the advanced or metastatic stages of NETs. Chemotherapy can help control symptoms, reduce tumor growth, and enhance the patient's quality of life, but treatment is not always curative. Moreover, targeted and individualized chemotherapy regimens are being investigated in order to reduce side effects and improve treatment outcomes for people with neuroendocrine tumors, which is boosting this segment's expansion.

The pancreatic neuroendocrine tumor segment is expected to have the highest CAGR during the forecast period

The pancreatic neuroendocrine tumor segment is anticipated to have the highest CAGR during the forecast period. These tumors arise from the endocrine cells of the pancreas, and their distinct characteristics necessitate specialized treatment considerations. Treatment approaches for pNETs involve a multidisciplinary strategy, considering factors such as tumor grade, stage, and functionality. Additionally, for advanced or metastatic pNETs, therapeutic options include somatostatin analogs, which help control hormone-related symptoms and inhibit pathways promoting tumor growth, which are driving this segment's growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to advanced diagnostic tools, such as PET-CT scans and molecular profiling that have enhanced the early detection and characterization of neuroendocrine tumors. Targeted therapies and immunotherapies have gained prominence, offering more effective and personalized treatment options. Furthermore, collaborative efforts among healthcare stakeholders, government bodies, and pharmaceutical companies are crucial to addressing these disparities and enhancing the overall NET treatment, which is driving this region's growth.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to government healthcare policies and insurance coverage that significantly influence patient access to these treatments. Key players such as Eli Lilly & Company, Novartis AG, Hutchison MediPharma Limited, and Pfizer Inc. are developing in a favorable environment due to the region's strict regulations and large public and private investments in healthcare and research. Regulatory bodies like the FDA (Food and Drug Administration) play a central role in drug and treatment device approvals, ensuring safety and efficacy, which are propelling this region's expansion.

Key players in the market

Some of the key players in the Neuroendocrine Tumor Treatment Market include Novartis AG, Exelixis, Inc., Boehringer Ingelheim International GmbH, Tarveda Therapeutics, Dauntless Pharmaceuticals, Hutchison MediPharma Limited, AVEO Oncology, Pfizer Inc., Ipsen Pharma, Progenics Pharmaceuticals, Inc., Eli Lilly & Company, Lantheus Holdings, Inc. and Jubilant Life Sciences Ltd.

Key Developments:

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

In August 2023, Novartis announced that it has completed its acquisition of Chinook

Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases.

In July 2023, Eli Lilly and Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

In July 2023, Flagship Pioneering, Inc. and Pfizer Inc. announced the companies have partnered to create a new pipeline of innovative medicines.

Therapies Covered:

Chemotherapy

Targeted Therapy

Somatostatin Analogues

Immunotherapy

Other Therapies

Disease Indications Covered:

Pancreatic Neuroendocrine Tumor

Lung Neuroendocrine Tumor

Gastrointestinal Neuroendocrine Tumor

Other Disease Indications

Route of Administrations Covered:

Parenteral

Oral

Site Analysis Covered:

Colon

Lungs

Small Intestine

Pancreas

Other Site Analysis

End Users Covered:

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY THERAPY

- 5.1 Introduction
- 5.2 Chemotherapy
- 5.3 Targeted Therapy
- 5.4 Somatostatin Analogues
- 5.5 Immunotherapy
- 5.6 Other Therapies

6 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY DISEASE INDICATION

- 6.1 Introduction
- 6.2 Pancreatic Neuroendocrine Tumor
- 6.3 Lung Neuroendocrine Tumor
- 6.4 Gastrointestinal Neuroendocrine Tumor
- 6.5 Other Disease Indications

7 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

- 7.1 Introduction
- 7.2 Parenteral
- 7.3 Oral

8 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY SITE ANALYSIS

- 8.1 Introduction
- 8.2 Colon
- 8.3 Lungs
- 8.4 Small Intestine
- 8.5 Pancreas
- 8.6 Other Site Analysis

9 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY END USER

- 9.1 Introduction
- 9.2 Hospital Pharmacy
- 9.3 Online Pharmacy

9.4 Retail Pharmacy

9.5 Other End Users

10 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY GEOGRAPHY

10.1 Introduction

10.2 North America

10.2.1 US

10.2.2 Canada

10.2.3 Mexico

10.3 Europe

10.3.1 Germany

10.3.2 UK

10.3.3 Italy

10.3.4 France

10.3.5 Spain

10.3.6 Rest of Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 New Zealand

10.4.6 South Korea

10.4.7 Rest of Asia Pacific

10.5 South America

10.5.1 Argentina

10.5.2 Brazil

10.5.3 Chile

10.5.4 Rest of South America

10.6 Middle East & Africa

10.6.1 Saudi Arabia

10.6.2 UAE

10.6.3 Qatar

10.6.4 South Africa

10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies

12 COMPANY PROFILING

- 12.1 Novartis AG
- 12.2 Exelixis, Inc.
- 12.3 Boehringer Ingelheim International GmbH
- 12.4 Tarveda Therapeutics
- 12.5 Dauntless Pharmaceuticals
- 12.6 Hutchison MediPharma Limited
- 12.7 AVEO Oncology
- 12.8 Pfizer Inc.
- 12.9 Ipsen Pharma
- 12.10 Progenics Pharmaceuticals, Inc.
- 12.11 Eli Lilly & Company
- 12.12 Lantheus Holdings, Inc.
- 12.13 Jubilant Life Sciences Ltd.

List Of Tables

LIST OF TABLES

- Table 1 Global Neuroendocrine Tumor Treatment Market Outlook, By Region (2023–2034) (\$MN)
- Table 2 Global Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023–2034) (\$MN)
- Table 3 Global Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023–2034) (\$MN)
- Table 4 Global Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023–2034) (\$MN)
- Table 5 Global Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023–2034) (\$MN)
- Table 6 Global Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023–2034) (\$MN)
- Table 7 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023–2034) (\$MN)
- Table 8 Global Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023–2034) (\$MN)
- Table 9 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023–2034) (\$MN)
- Table 10 Global Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023–2034) (\$MN)
- Table 11 Global Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023–2034) (\$MN)
- Table 12 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023–2034) (\$MN)
- Table 13 Global Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023–2034) (\$MN)
- Table 14 Global Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023–2034) (\$MN)
- Table 15 Global Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023–2034) (\$MN)
- Table 16 Global Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023–2034) (\$MN)
- Table 17 Global Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023–2034) (\$MN)
- Table 18 Global Neuroendocrine Tumor Treatment Market Outlook, By Lungs

(2023–2034) (\$MN)

Table 19 Global Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023–2034) (\$MN)

Table 20 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023–2034) (\$MN)

Table 21 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023–2034) (\$MN)

Table 22 Global Neuroendocrine Tumor Treatment Market Outlook, By End User (2023–2034) (\$MN)

Table 23 Global Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023–2034) (\$MN)

Table 24 Global Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023–2034) (\$MN)

Table 25 Global Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023–2034) (\$MN)

Table 26 Global Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 27 North America Neuroendocrine Tumor Treatment Market Outlook, By Country (2023–2034) (\$MN)

Table 28 North America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023–2034) (\$MN)

Table 29 North America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023–2034) (\$MN)

Table 30 North America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023–2034) (\$MN)

Table 31 North America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023–2034) (\$MN)

Table 32 North America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023–2034) (\$MN)

Table 33 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023–2034) (\$MN)

Table 34 North America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023–2034) (\$MN)

Table 35 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023–2034) (\$MN)

Table 36 North America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023–2034) (\$MN)

Table 37 North America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023–2034) (\$MN)

Table 38 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023–2034) (\$MN)

Table 39 North America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 40 North America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023–2034) (\$MN)

Table 41 North America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023–2034) (\$MN)

Table 42 North America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023–2034) (\$MN)

Table 43 North America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023–2034) (\$MN)

Table 44 North America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023–2034) (\$MN)

Table 45 North America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023–2034) (\$MN)

Table 46 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023–2034) (\$MN)

Table 47 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023–2034) (\$MN)

Table 48 North America Neuroendocrine Tumor Treatment Market Outlook, By End User (2023–2034) (\$MN)

Table 49 North America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023–2034) (\$MN)

Table 50 North America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023–2034) (\$MN)

Table 51 North America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023–2034) (\$MN)

Table 52 North America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 53 Europe Neuroendocrine Tumor Treatment Market Outlook, By Country (2023–2034) (\$MN)

Table 54 Europe Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023–2034) (\$MN)

Table 55 Europe Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023–2034) (\$MN)

Table 56 Europe Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023–2034) (\$MN)

Table 57 Europe Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin

Analogues (2023–2034) (\$MN)

Table 58 Europe Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023–2034) (\$MN)

Table 59 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023–2034) (\$MN)

Table 60 Europe Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023–2034) (\$MN)

Table 61 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023–2034) (\$MN)

Table 62 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023–2034) (\$MN)

Table 63 Europe Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023–2034) (\$MN)

Table 64 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023–2034) (\$MN)

Table 65 Europe Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 66 Europe Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023–2034) (\$MN)

Table 67 Europe Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023–2034) (\$MN)

Table 68 Europe Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023–2034) (\$MN)

Table 69 Europe Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023–2034) (\$MN)

Table 70 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023–2034) (\$MN)

Table 71 Europe Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023–2034) (\$MN)

Table 72 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023–2034) (\$MN)

Table 73 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023–2034) (\$MN)

Table 74 Europe Neuroendocrine Tumor Treatment Market Outlook, By End User (2023–2034) (\$MN)

Table 75 Europe Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023–2034) (\$MN)

Table 76 Europe Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023–2034) (\$MN)

Table 77 Europe Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023–2034) (\$MN)

Table 78 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 79 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Country (2023–2034) (\$MN)

Table 80 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023–2034) (\$MN)

Table 81 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023–2034) (\$MN)

Table 82 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023–2034) (\$MN)

Table 83 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023–2034) (\$MN)

Table 84 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023–2034) (\$MN)

Table 85 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023–2034) (\$MN)

Table 86 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023–2034) (\$MN)

Table 87 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023–2034) (\$MN)

Table 88 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023–2034) (\$MN)

Table 89 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023–2034) (\$MN)

Table 90 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023–2034) (\$MN)

Table 91 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 92 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023–2034) (\$MN)

Table 93 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023–2034) (\$MN)

Table 94 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023–2034) (\$MN)

Table 95 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023–2034) (\$MN)

Table 96 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lungs

(2023–2034) (\$MN)

Table 97 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023–2034) (\$MN)

Table 98 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023–2034) (\$MN)

Table 99 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023–2034) (\$MN)

Table 100 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By End User (2023–2034) (\$MN)

Table 101 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023–2034) (\$MN)

Table 102 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023–2034) (\$MN)

Table 103 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023–2034) (\$MN)

Table 104 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 105 South America Neuroendocrine Tumor Treatment Market Outlook, By Country (2023–2034) (\$MN)

Table 106 South America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023–2034) (\$MN)

Table 107 South America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023–2034) (\$MN)

Table 108 South America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023–2034) (\$MN)

Table 109 South America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023–2034) (\$MN)

Table 110 South America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023–2034) (\$MN)

Table 111 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023–2034) (\$MN)

Table 112 South America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023–2034) (\$MN)

Table 113 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023–2034) (\$MN)

Table 114 South America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023–2034) (\$MN)

Table 115 South America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023–2034) (\$MN)

- Table 116 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023–2034) (\$MN)
- Table 117 South America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023–2034) (\$MN)
- Table 118 South America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023–2034) (\$MN)
- Table 119 South America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023–2034) (\$MN)
- Table 120 South America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023–2034) (\$MN)
- Table 121 South America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023–2034) (\$MN)
- Table 122 South America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023–2034) (\$MN)
- Table 123 South America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023–2034) (\$MN)
- Table 124 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023–2034) (\$MN)
- Table 125 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023–2034) (\$MN)
- Table 126 South America Neuroendocrine Tumor Treatment Market Outlook, By End User (2023–2034) (\$MN)
- Table 127 South America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023–2034) (\$MN)
- Table 128 South America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023–2034) (\$MN)
- Table 129 South America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023–2034) (\$MN)
- Table 130 South America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023–2034) (\$MN)
- Table 131 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Country (2023–2034) (\$MN)
- Table 132 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023–2034) (\$MN)
- Table 133 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023–2034) (\$MN)
- Table 134 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023–2034) (\$MN)
- Table 135 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By

Somatostatin Analogues (2023–2034) (\$MN)

Table 136 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023–2034) (\$MN)

Table 137 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023–2034) (\$MN)

Table 138 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023–2034) (\$MN)

Table 139 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023–2034) (\$MN)

Table 140 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023–2034) (\$MN)

Table 141 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023–2034) (\$MN)

Table 142 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023–2034) (\$MN)

Table 143 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 144 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023–2034) (\$MN)

Table 145 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023–2034) (\$MN)

Table 146 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023–2034) (\$MN)

Table 147 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023–2034) (\$MN)

Table 148 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023–2034) (\$MN)

Table 149 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023–2034) (\$MN)

Table 150 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023–2034) (\$MN)

Table 151 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023–2034) (\$MN)

Table 152 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By End User (2023–2034) (\$MN)

Table 153 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023–2034) (\$MN)

Table 154 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023–2034) (\$MN)

Table 155 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023–2034) (\$MN)

Table 156 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023–2034) (\$MN)

I would like to order

Product name: Neuroendocrine Tumor Treatment Market Forecasts to 2034 – Global Analysis By Service (Safety Pharmacology, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies, Toxicology Testing, Chemistry, Compound Management and Other Services), Animal Model (Large Animal Model and Small Animal Model), Model Type, End User and By Geography

Product link: <https://marketpublishers.com/r/N523FEC6322AEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N523FEC6322AEN.html>